1
NR565 Week 4 Midterm Exam Review Examplify Online
Proctored Exam ,NR 565 Advanced Pharmacology
Fundamentals | 100% Pass Guaranteed | Graded A+
Question and Correct Answers.
How to Use This Review
This comprehensive question bank mirrors the structure and content of the
NR565 Week 4 Midterm Exam. Each question includes the correct ✔✔ Correct
Answer ✔✔ r and a detailed rationale to reinforce your understanding of
advanced pharmacology principles. Use active recall and spaced repetition to
maximize retention.
DOMAIN 1: PHARMACOKINETICS & PHARMACODYNAMICS
Q1: A patient is prescribed a drug that is a weak base with a pKa of 8.4. In which
part of the body will this drug be most highly ionized?
• ✔✔ Correct Answer ✔✔ r: Stomach (pH 1.5–3.5)
• Rationale: Weak bases are more ionized in acidic environments (low pH).
Ionized drugs are poorly absorbed. This has implications for absorption and
urinary excretion.
Q2: Which pharmacokinetic process is most affected by first-pass metabolism?
• ✔✔ Correct Answer ✔✔ r: Oral absorption
• Rationale: First-pass metabolism occurs in the liver and gut wall after oral
administration, reducing the amount of active drug reaching systemic
circulation. Drugs with extensive first-pass effect often require higher oral
doses or alternative routes.
,2
Q3: A drug has a volume of distribution (Vd) of 40 L. What does this indicate
about the drug’s distribution?
• ✔✔ Correct Answer ✔✔ r: It distributes into total body water.
• Rationale: Vd approximates 0.6 L/kg (42 L for 70 kg adult) suggests
distribution into both intracellular and extracellular fluid. High Vd indicates
extensive tissue binding; low Vd indicates confinement to plasma.
Q4: Which cytochrome P450 enzyme is responsible for metabolizing
approximately 50% of all marketed drugs?
• ✔✔ Correct Answer ✔✔ r: CYP3A4
• Rationale: CYP3A4 is the most abundant hepatic and intestinal CYP
enzyme, involved in the metabolism of many drugs, including statins,
calcium channel blockers, and immunosuppressants.
Q5: A patient with end-stage renal disease requires a drug that is primarily
renally excreted. What adjustment is typically required?
• ✔✔ Correct Answer ✔✔ r: Reduce the dose or increase the dosing
interval.
• Rationale: When creatinine clearance is reduced, drug accumulation
occurs. Dose adjustment based on estimated GFR maintains therapeutic
levels without toxicity.
Q6: What is the clinical significance of the therapeutic index (TI)?
• ✔✔ Correct Answer ✔✔ r: A narrow TI indicates a small margin
between therapeutic and toxic doses.
• Rationale: Drugs with narrow TI (e.g., warfarin, digoxin, phenytoin) require
careful monitoring of serum levels to avoid toxicity while ensuring efficacy.
Q7: Which term describes the phenomenon where one drug alters the
absorption, distribution, metabolism, or excretion of another drug?
• ✔✔ Correct Answer ✔✔ r: Pharmacokinetic drug interaction
,3
• Rationale: Pharmacokinetic interactions affect ADME; pharmacodynamic
interactions alter the drug effect without changing concentration.
Q8: A drug that is a substrate of P-glycoprotein (P-gp) will have what effect on
absorption?
• ✔✔ Correct Answer ✔✔ r: Decreased absorption
• Rationale: P-gp is an efflux transporter in the intestine, liver, and kidney
that pumps drugs back into the intestinal lumen, reducing bioavailability.
Inhibiting P-gp can increase drug absorption.
Q9: Which pharmacokinetic parameter is used to calculate the loading dose?
• ✔✔ Correct Answer ✔✔ r: Volume of distribution (Vd)
• Rationale: Loading dose = (desired concentration × Vd) / bioavailability. It is
independent of clearance.
Q10: A patient is taking a drug with a half-life of 24 hours. Approximately how
long will it take to reach steady state?
• ✔✔ Correct Answer ✔✔ r: 5 days (120 hours)
• Rationale: Steady state is reached after approximately 4–5 half-lives. A
24-hour half-life yields steady state in 4–5 days.
DOMAIN 2: AUTONOMIC NERVOUS SYSTEM DRUGS
Q11: Which receptor is primarily responsible for vasoconstriction when
stimulated by norepinephrine?
• ✔✔ Correct Answer ✔✔ r: Alpha-1 adrenergic receptor
• Rationale: Alpha-1 receptors on vascular smooth muscle mediate
vasoconstriction. Activation increases systemic vascular resistance and
blood pressure.
, 4
Q12: A patient taking a beta-1 selective antagonist (metoprolol) for heart
failure. Which adverse effect is most likely?
• ✔✔ Correct Answer ✔✔ r: Bradycardia
• Rationale: Beta-1 blockade decreases heart rate, contractility, and AV
conduction. Cardioselective agents have less effect on beta-2 receptors
(bronchial, vascular).
Q13: Which cholinergic receptor is found at the neuromuscular junction?
• ✔✔ Correct Answer ✔✔ r: Nicotinic (Nn and Nm)
• Rationale: Nicotinic receptors are ligand-gated ion channels. Nm receptors
at the neuromuscular junction mediate skeletal muscle contraction; Nn
receptors in autonomic ganglia and adrenal medulla.
Q14: Atropine, a muscarinic antagonist, is used to treat bradycardia. What is its
mechanism?
• ✔✔ Correct Answer ✔✔ r: Blocks acetylcholine at cardiac muscarinic
(M2) receptors, increasing heart rate.
• Rationale: Parasympathetic tone (vagus) slows heart rate via M2 receptors.
Atropine antagonizes this effect, allowing sympathetic dominance and
increased rate.
Q15: A patient receiving albuterol for asthma complains of tremor. What is the
mechanism?
• ✔✔ Correct Answer ✔✔ r: Beta-2 receptor stimulation in skeletal
muscle
• Rationale: Albuterol is beta-2 selective, but at higher doses beta-1 and
beta-2 effects occur. Tremor is a common dose-related side effect due to
beta-2 stimulation of muscle spindles.
Q16: What is the primary clinical use of a non-selective alpha-blocker like
prazosin?
• ✔✔ Correct Answer ✔✔ r: Hypertension (and benign prostatic
hyperplasia)
NR565 Week 4 Midterm Exam Review Examplify Online
Proctored Exam ,NR 565 Advanced Pharmacology
Fundamentals | 100% Pass Guaranteed | Graded A+
Question and Correct Answers.
How to Use This Review
This comprehensive question bank mirrors the structure and content of the
NR565 Week 4 Midterm Exam. Each question includes the correct ✔✔ Correct
Answer ✔✔ r and a detailed rationale to reinforce your understanding of
advanced pharmacology principles. Use active recall and spaced repetition to
maximize retention.
DOMAIN 1: PHARMACOKINETICS & PHARMACODYNAMICS
Q1: A patient is prescribed a drug that is a weak base with a pKa of 8.4. In which
part of the body will this drug be most highly ionized?
• ✔✔ Correct Answer ✔✔ r: Stomach (pH 1.5–3.5)
• Rationale: Weak bases are more ionized in acidic environments (low pH).
Ionized drugs are poorly absorbed. This has implications for absorption and
urinary excretion.
Q2: Which pharmacokinetic process is most affected by first-pass metabolism?
• ✔✔ Correct Answer ✔✔ r: Oral absorption
• Rationale: First-pass metabolism occurs in the liver and gut wall after oral
administration, reducing the amount of active drug reaching systemic
circulation. Drugs with extensive first-pass effect often require higher oral
doses or alternative routes.
,2
Q3: A drug has a volume of distribution (Vd) of 40 L. What does this indicate
about the drug’s distribution?
• ✔✔ Correct Answer ✔✔ r: It distributes into total body water.
• Rationale: Vd approximates 0.6 L/kg (42 L for 70 kg adult) suggests
distribution into both intracellular and extracellular fluid. High Vd indicates
extensive tissue binding; low Vd indicates confinement to plasma.
Q4: Which cytochrome P450 enzyme is responsible for metabolizing
approximately 50% of all marketed drugs?
• ✔✔ Correct Answer ✔✔ r: CYP3A4
• Rationale: CYP3A4 is the most abundant hepatic and intestinal CYP
enzyme, involved in the metabolism of many drugs, including statins,
calcium channel blockers, and immunosuppressants.
Q5: A patient with end-stage renal disease requires a drug that is primarily
renally excreted. What adjustment is typically required?
• ✔✔ Correct Answer ✔✔ r: Reduce the dose or increase the dosing
interval.
• Rationale: When creatinine clearance is reduced, drug accumulation
occurs. Dose adjustment based on estimated GFR maintains therapeutic
levels without toxicity.
Q6: What is the clinical significance of the therapeutic index (TI)?
• ✔✔ Correct Answer ✔✔ r: A narrow TI indicates a small margin
between therapeutic and toxic doses.
• Rationale: Drugs with narrow TI (e.g., warfarin, digoxin, phenytoin) require
careful monitoring of serum levels to avoid toxicity while ensuring efficacy.
Q7: Which term describes the phenomenon where one drug alters the
absorption, distribution, metabolism, or excretion of another drug?
• ✔✔ Correct Answer ✔✔ r: Pharmacokinetic drug interaction
,3
• Rationale: Pharmacokinetic interactions affect ADME; pharmacodynamic
interactions alter the drug effect without changing concentration.
Q8: A drug that is a substrate of P-glycoprotein (P-gp) will have what effect on
absorption?
• ✔✔ Correct Answer ✔✔ r: Decreased absorption
• Rationale: P-gp is an efflux transporter in the intestine, liver, and kidney
that pumps drugs back into the intestinal lumen, reducing bioavailability.
Inhibiting P-gp can increase drug absorption.
Q9: Which pharmacokinetic parameter is used to calculate the loading dose?
• ✔✔ Correct Answer ✔✔ r: Volume of distribution (Vd)
• Rationale: Loading dose = (desired concentration × Vd) / bioavailability. It is
independent of clearance.
Q10: A patient is taking a drug with a half-life of 24 hours. Approximately how
long will it take to reach steady state?
• ✔✔ Correct Answer ✔✔ r: 5 days (120 hours)
• Rationale: Steady state is reached after approximately 4–5 half-lives. A
24-hour half-life yields steady state in 4–5 days.
DOMAIN 2: AUTONOMIC NERVOUS SYSTEM DRUGS
Q11: Which receptor is primarily responsible for vasoconstriction when
stimulated by norepinephrine?
• ✔✔ Correct Answer ✔✔ r: Alpha-1 adrenergic receptor
• Rationale: Alpha-1 receptors on vascular smooth muscle mediate
vasoconstriction. Activation increases systemic vascular resistance and
blood pressure.
, 4
Q12: A patient taking a beta-1 selective antagonist (metoprolol) for heart
failure. Which adverse effect is most likely?
• ✔✔ Correct Answer ✔✔ r: Bradycardia
• Rationale: Beta-1 blockade decreases heart rate, contractility, and AV
conduction. Cardioselective agents have less effect on beta-2 receptors
(bronchial, vascular).
Q13: Which cholinergic receptor is found at the neuromuscular junction?
• ✔✔ Correct Answer ✔✔ r: Nicotinic (Nn and Nm)
• Rationale: Nicotinic receptors are ligand-gated ion channels. Nm receptors
at the neuromuscular junction mediate skeletal muscle contraction; Nn
receptors in autonomic ganglia and adrenal medulla.
Q14: Atropine, a muscarinic antagonist, is used to treat bradycardia. What is its
mechanism?
• ✔✔ Correct Answer ✔✔ r: Blocks acetylcholine at cardiac muscarinic
(M2) receptors, increasing heart rate.
• Rationale: Parasympathetic tone (vagus) slows heart rate via M2 receptors.
Atropine antagonizes this effect, allowing sympathetic dominance and
increased rate.
Q15: A patient receiving albuterol for asthma complains of tremor. What is the
mechanism?
• ✔✔ Correct Answer ✔✔ r: Beta-2 receptor stimulation in skeletal
muscle
• Rationale: Albuterol is beta-2 selective, but at higher doses beta-1 and
beta-2 effects occur. Tremor is a common dose-related side effect due to
beta-2 stimulation of muscle spindles.
Q16: What is the primary clinical use of a non-selective alpha-blocker like
prazosin?
• ✔✔ Correct Answer ✔✔ r: Hypertension (and benign prostatic
hyperplasia)
